- Home
- AIM vs COCP Comparison
AIM vs COCP Comparison
Compare AIM & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- COCP
- Stock Information
- Founded
- AIM 1966
- COCP N/A
- Country
- AIM United States
- COCP United States
- Employees
- AIM N/A
- COCP N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- AIM Health Care
- COCP Health Care
- Exchange
- AIM Nasdaq
- COCP Nasdaq
- Market Cap
- AIM 15.9M
- COCP 18.3M
- IPO Year
- AIM N/A
- COCP N/A
- Fundamental
- Price
- AIM $0.22
- COCP $2.15
- Analyst Decision
- AIM Strong Buy
- COCP Strong Buy
- Analyst Count
- AIM 2
- COCP 1
- Target Price
- AIM $3.00
- COCP $7.00
- AVG Volume (30 Days)
- AIM 295.4K
- COCP 22.2K
- Earning Date
- AIM 11-15-2024
- COCP 11-13-2024
- Dividend Yield
- AIM N/A
- COCP N/A
- EPS Growth
- AIM N/A
- COCP N/A
- EPS
- AIM N/A
- COCP N/A
- Revenue
- AIM $190,000.00
- COCP N/A
- Revenue This Year
- AIM N/A
- COCP N/A
- Revenue Next Year
- AIM $1,086.80
- COCP N/A
- P/E Ratio
- AIM N/A
- COCP N/A
- Revenue Growth
- AIM N/A
- COCP N/A
- 52 Week Low
- AIM $0.21
- COCP $1.33
- 52 Week High
- AIM $0.62
- COCP $3.10
- Technical
- Relative Strength Index (RSI)
- AIM 35.93
- COCP 64.04
- Support Level
- AIM $0.24
- COCP $1.65
- Resistance Level
- AIM $0.27
- COCP $1.82
- Average True Range (ATR)
- AIM 0.02
- COCP 0.17
- MACD
- AIM -0.00
- COCP 0.03
- Stochastic Oscillator
- AIM 7.49
- COCP 64.10
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).